NEWTON, Mass.--(BUSINESS WIRE)--Pro-Pharmaceuticals, Inc. (Amex: PRW), today announced that data of all end-stage colorectal cancer patients from its Phase II trial showed DAVANAT®, administered in combination with 5-fluorouracil (5-FU), extended median survival by 6.7 months or 29 weeks after all other treatments were exhausted. The data for the 20 patients that completed the trial revealed that three patients survived more than one year, two patients survived more than two years and one patient is still alive.
